Your session is about to expire
← Back to Search
Nefecon for IgA Nephropathy (Nefigard Trial)
Nefigard Trial Summary
This trial is testing a new drug to see if it can help people with Immunoglobulin A nephropathy (a kidney disease) who are at risk of progressing to end-stage renal disease, and who are already taking the maximum tolerated doses of other drugs.
- IgA Nephropathy
Nefigard Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowNefigard Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Nefigard Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How does Nefecon compare to other options in terms of safety?
"Nefecon received a safety score of 3 because it has reached Phase 3 in clinical trials. This indicates that not only is there some evidence supporting its efficacy, but also that there is ample evidence indicating that it is safe."
How many more people can join this trial?
"As of December 10th 2021, this clinical trial is no longer recruiting patients. If you are interested in other research studies, there are currently 501 trials for iga glomerulonephritis and 32 for Nefecon admitting new participants."
What are the most similar medical trials to Nefecon?
"Currently, there are 32 trials in progress for Nefecon. 10 of them are in Phase 3. Although the majority of studies for Nefecon are based in Xi'an, Shaanxi, there are 992 locations running studies for this treatment."
What conditions does Nefecon help ameliorate?
"Nefecon is an effective medication for acute coryza and can also help patients with proteinuria, nasal congestion, and crohn disease."
Share this study with friends
Copy Link
Messenger